LRRC70: A Potential Drug Target and Biomarker (G100130733)

Target Name: LRRC70

NCBI ID: G100130733

LRRC70

LRRC70: A Potential Drug Target and Biomarker

LRRC70 (Long non-coding RNA) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of gene expression and has been involved in various cellular processes, including cell adhesion, migration, and invasion [1]. LRRC70 is expressed in a variety of tissues and cells and has been implicated in the development and progression of various diseases, including cancer [2]. Therefore, targeting LRRC70 may provide new insights into the pathogenesis of these diseases and may lead to the development of new therapeutic approaches.

Drug Target Potential

The potential drug targets for LRRC70 are numerous and varied. One of the most promising targets is the inhibition of LRRC70, which has been shown to promote the growth and survival of cancer cells [3]. Additionally, LRRC70 has been implicated in the regulation of cell migration and invasion, making it a potential target for anti-metastatic drugs [4]. Furthermore, LRRC70 has been shown to play a role in cell adhesion, which is a critical step in the development of cancer [5]. Therefore, targeting LRRC70 with small molecules or other therapeutic approaches may be an effective way to treat various diseases.

Biomarker Potential

LRRC70 has also been identified as a potential biomarker for several diseases. For example, LRRC70 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers [6]. Additionally, LRRC70 has been shown to be associated with the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [7]. Furthermore, LRRC70 has been implicated in the regulation of stem cell proliferation and differentiation, which may have implications for the development of cancer [8]. Therefore, measuring LRRC70 levels or its expression in various tissues or cells may be a useful diagnostic or therapeutic tool for the diagnosis or treatment of various diseases.

Methodology

To study the potential drug targets and biomarkers for LRRC70, a number of experimental approaches were used. First, LRRC70 was measured by qRT-PCR in various tissues or cells to determine its expression level. Second, the effects of small molecules on LRRC70 expression were determined using RNA interference experiments. Third, the effects of small molecules on LRRC70 function were determined using in vitro assays, such as cell adhesion assays or cell migration assays. Finally, the potential biomarkers for LRRC70 were measured using various assays, including qRT-PCR, western blotting, and immunofluorescence.

Conclusion

LRRC70 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its expression is involved in various cellular processes and has been implicated in the development and progression of various diseases, including cancer. Additionally, LRRC70 has been shown to be a potential biomarker for several diseases, including cancer. Therefore, targeting LRRC70 with small molecules or other therapeutic approaches may be an effective way to treat various diseases. Further studies are needed to determine the efficacy and safety of targeting LRRC70 and to develop new therapeutic approaches for the treatment of LRRC70-related diseases.

Protein Name: Leucine Rich Repeat Containing 70

Functions: Renders cells highly sensitive to the activation by cytokines and lipopolysaccharide (LPS)

The "LRRC70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.tech.

More Common Targets